Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

This study aims to understand whether it is possible to predict the effectiveness of maintenance treatment with PARP inhibitors following first-line chemotherapy in ovarian cancer, and thus better target the patients who benefit from this treatment

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ovarian Cancer Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Diseases Ovarian Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

ICO Paul Papin, Angers, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients randomised in the PAOLA-1 study -

Exclusion criteria

Opposition to the use of your data for research purposes.

Treatment and study plan

Primary outcomes

predictive and prognostic value of the KELIM score

Time frame: 18 months

To evaluate the predictive and prognostic value of the KELIM score in patients receiving maintenance treatment with a PARP inhibitor as part of the PAOLA-1 clinical trial.

Sponsors and collaborators

Lead sponsor

ARCAGY/ GINECO GROUP

Other

Registry information

Official study title

PAOLA-1 Ancillary Study: Retrospective Validation of KELIM as a Predictive and Prognostic Factor for Maintenance Treatment With PARP Inhibitor After Platinum-Based Chemotherapy in First-Line Ovarian Cancer

Acronym: KELI-PAOLA

Important dates

Study start: 2023
Primary completion: 2025
Study completion: 2025
First posted: Oct 28, 2024
Registry last updated: Jun 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed